Cholangiocarcinoma News
October 10, 2022: IMPORTANT INFORMATION ABOUT TRUSELTIQ

READ MORE

Highlights from the Latest Issue: December 2022, Vol 3, No 4

Latest Web Exclusive Articles

The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial
 ESMO Highlights
Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
Read More ›
Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2
 ESMO Highlights
Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.
Read More ›
Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations
 ESMO Highlights
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.
Read More ›
View All

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly CCA News print publication and CCA News weekly e‑newsletter.

© Amplity Health. All Rights Reserved. Privacy Policy.